Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

Published:2009-04 Issue:4 Volume:28 Page:267-272
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Abarca Katia,Jung Elizabeth,Fernández Pilar,Zhao Liang,Harris Brian,Connor Edward M.,Losonsky Genevieve A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health

Reference11 articles.

1. The changing epidemiology of respiratory syncytial virus and influenza: impetus for new control measures.;Glezen;Pediatr Infect Dis J,2004

2. Respiratory syncytial and parainfluenza viruses.;Heilman;J Infect Dis,1990

3. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.;Groothuis;Pediatrics,1988

4. Red Book: Report of the Committee on Infectious Diseases. 25th ed.,2000

5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.;Pediatrics,1998

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevention of fetal and early life infections through maternal-neonatal immunization;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Systematic Review of the Efficacy and Safety of RSV‐Specific Monoclonal Antibodies and Antivirals in Development;Reviews in Medical Virology;2024-08-29

3. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy;Journal of the Pediatric Infectious Diseases Society;2024-07-12

4. Current state and challenges in respiratory syncytial virus drug discovery and development;Antiviral Research;2024-01

5. Prevención de la infección por virus respiratorio sincicial en lactantes. ¿Qué se ha hecho y en qué estamos hoy?;Andes Pediatrica;2023-12-21